ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   
 News | News By Subject | News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Roche (RHHBY)'s Zelboraf May Double Survival for Some Melanoma Patients


2/23/2012 7:04:34 AM

The newly approved drug Zelboraf appears to nearly double the length of time a person can expect to live with advanced melanoma skin cancer, a new study shows. Melanoma kills about 9,000 Americans each year, and it often progresses quickly. Studies have found that the midpoint in survival time for patients on standard chemotherapy is just six to 10 months for patients with melanoma that has spread to other organs. Last year, the FDA fast-tracked approval for Zelboraf, a pill that targets a specific mutation in the BRAF gene that’s present in about half of all melanomas.

Read at WebMD
Read at BBC News
Read at News Release
Read at CBS News
Read at MedicalXpress


 Read Article at  Related Companies  News Categories
Roche
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES